Real-World data on ribociclib combo for breast cancer in middle east
NCT ID NCT06075758
First seen May 15, 2026 · Last updated May 19, 2026 · Updated 3 times
Summary
This study observed 175 adults with HR+/HER2- advanced or metastatic breast cancer in the Middle East who received ribociclib plus hormone therapy. Researchers tracked side effects and how long the cancer stayed under control. The goal was to see how well this treatment works in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Muscat, 111, Oman
-
Novartis Investigative Site
Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
Conditions
Explore the condition pages connected to this study.